NasdaqGS:SANABiotechs
Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors
Sana Biotechnology (NasdaqGS:SANA) reported 12 month results from its UP421 type 1 diabetes trial, showing hypoimmune pancreatic islet cells functioning for a year without immunosuppression.
The company outlined plans to move next generation cell therapy candidates for diabetes and cancer into further clinical development.
Sana named a new chief financial officer and amended its equity sales agreement alongside a new shelf registration to expand capital raising flexibility.
Sana...